Bringing breakthrough immunotherapies to patients with cancer

Vicus is employing immunotherapy to selectively target signaling pathways that lead to tumor-promoting inflammation, tumor immune escape and inflammation-potentiated toxicities. Our goal is to bring breakthrough immunotherapies to patients with cancer.

We are an immuno-oncology company developing breakthrough immunotherapies for patients with solid-tumor cancers. We are focused on the development and commercialization of our lead product candidate, VT-122, the first multi-pathway neuro-immune  modulator, for advanced liver cancer patients receiving sorafenib and for metastatic pancreatic cancer patients receiving nab-paclitaxel  and gemcitabine.